Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

365 Press Releases
DateTitleCompany
01 Oct 15 New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Oct 15 ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status Boehringer Ingelheim ,
Published by
PharmiWeb.com
29 Sep 15 New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
28 Sep 15 New Head-to-Head STIOLTO RESPIMAT Data Presented at ERS Annual Congress Boehringer Ingelheim Pharmaceuticals, Inc.,
Published by
PR Newswire
28 Sep 15 COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS Boehringer Ingelheim,
Published by
Business Wire
27 Sep 15 ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status Boehringer Ingelheim,
Published by
Business Wire
27 Sep 15 VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first-line chemotherapy Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 Extending overall survival is less important than quality of life and disease stability for the majority of physicians treating patients with advanced lung cancer following first line-chemotherapy Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) Boehringer Ingelheim,
Published by
Business Wire
25 Sep 15 CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) Boehringer Ingelheim Limited,
Published by
Business Wire
24 Sep 15 Boehringer Ingelheim Named to 2015 Working Mother 100 Best Companies Boehringer Ingelheim ,
Published by
PharmiWeb.com
23 Sep 15 ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments Boehringer Ingelheim ,
Published by
Pharmiweb.com
23 Sep 15 Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD Boehringer Ingelheim ,
Published by
Pharmiweb.com
23 Sep 15 Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe Boehringer Ingelheim ,
Published by
Pharmiweb.com
20 Aug 15 Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events Boehringer Ingelheim,
Published by
Business Wire
29 Aug 15 Expansion of the Boehringer Ingelheim Board of Managing Directors / Andreas Neumann responsible for Human Resources Boehringer Ingelheim ,
Published by
Pharmiweb.com
29 Aug 15 ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim Boehringer Ingelheim,
Published by
Business Wire
25 Aug 15 FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung Boehringer Ingelheim,
Published by
Pharmiweb.com
17 Sep 15 New data demonstrates Jardiance®? (empagliflozin) showed a significant reduction in cardiovascular risk in diabetes patients in a dedicated outcome trial Boehringer Ingelheim,
Published by
Business Wire
17 Sep 15 Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial Boehringer Ingelheim,
Published by
Business Wire
03 Sep 15 ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim Boehringer Ingelheim ,
Published by
PharmiWeb.com
03 Sep 15 Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Sep 15 Boehringer Ingelheim: New Data Show That More Than 50% of Patients and Carers Struggled to Cope with Challenges of Living with Lung Cancer Boehringer Ingelheim,
Published by
Business Wire
21 Sep 15 ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments Boehringer Ingelheim,
Published by
Business Wire
21 Sep 15 Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD Boehringer Ingelheim,
Published by
Business Wire
09 Sep 15 New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer Boehringer Ingelheim ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.